Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

Inclusion criteria

• ✓. Willing and able to provide written informed consent
• ✓. Male or female, age ≥18 years
• ✓. HCV RNA ≥ 15 IU/mL at Screening
• ✓. HCV genotype 1
• ✓. Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy
• ✓. Classification as treatment naïve or treatment experienced:
• ✓. Treatment naïve is defined as having never been exposed to approved or experimental HCV-specific direct-acting antiviral agents or prior treatment of HCV with interferon or ribavirin or DAAs (except for SOF-containing regimens).
• ✓. Treatment experienced is defined as prior treatment failure or relapse to a regimen containing interferon either with or without RBV or DAAs (except for SOF-containing regimens) that was completed at least 8 weeks prior to Baseline/Day 1.